These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24659500)

  • 1. In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.
    Senćanski M; Dosen-Mićović L
    Protein J; 2014 Jun; 33(3):231-42. PubMed ID: 24659500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids.
    Mollereau C; Moisand C; Butour JL; Parmentier M; Meunier JC
    FEBS Lett; 1996 Oct; 395(1):17-21. PubMed ID: 8849681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tritium-labelled isovaleryl-RYYRIK-NH2 as potential antagonist probe for ORL1 nociceptin receptor.
    Inamine S; Nishimura H; Li J; Isozaki K; Matsushima A; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2014 Nov; 22(21):5902-9. PubMed ID: 25284251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
    Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
    Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capturing of the free cysteine residue in the ligand-binding site by affinity labeling of the ORL1 nociceptin receptor.
    Matsushima A; Nishimura H; Inamine S; Uemura S; Shimohigashi Y
    Bioorg Med Chem; 2011 Dec; 19(24):7597-602. PubMed ID: 22061823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.
    Zaveri N; Jiang F; Olsen C; Polgar W; Toll L
    AAPS J; 2005 Oct; 7(2):E345-52. PubMed ID: 16353914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
    Daga PR; Zaveri NT
    Proteins; 2012 Aug; 80(8):1948-61. PubMed ID: 22489047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modelling of the ORL1 receptor and its complex with nociceptin.
    Topham CM; Moulédous L; Poda G; Maigret B; Meunier JC
    Protein Eng; 1998 Dec; 11(12):1163-79. PubMed ID: 9930666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
    Daga PR; Polgar WE; Zaveri NT
    J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid receptor-like 1 (ORL1) molecular "road map" to understanding ligand interaction and selectivity.
    Philip AE; Poupaert JH; McCurdy CR
    Curr Top Med Chem; 2005; 5(3):325-40. PubMed ID: 15857315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-methylthioacetylation of RYYRIK-NH2 with enhanced specific binding affinity and high antagonist activity for nociceptin ORL1 receptor.
    Li J; Nishimura H; Matsushima A; Shimohigashi Y
    Bioorg Med Chem; 2014 Nov; 22(21):5721-6. PubMed ID: 25319085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modelling studies on the ORL1-receptor and ORL1-agonists.
    Bröer BM; Gurrath M; Höltje HD
    J Comput Aided Mol Des; 2003 Nov; 17(11):739-54. PubMed ID: 15072434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different domains of the ORL1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A.
    Lapalu S; Moisand C; Butour JL; Mollereau C; Meunier JC
    FEBS Lett; 1998 May; 427(2):296-300. PubMed ID: 9607332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on mechanism of interaction of nociceptin and opioids binding with opioid receptor-like 1 receptor.
    Huang XQ; Jiang HL; Luo XM; Chen KX; Zhu YC; Ji RY; Cao Y
    Acta Pharmacol Sin; 2000 Jun; 21(6):536-46. PubMed ID: 11360688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nociceptin receptor (NOPR) and its interaction with clinically important agonist molecules: a membrane molecular dynamics simulation study.
    Kothandan G; Gadhe CG; Balupuri A; Ganapathy J; Cho SJ
    Mol Biosyst; 2014 Dec; 10(12):3188-98. PubMed ID: 25259728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.
    Zaveri N
    Life Sci; 2003 Jun; 73(6):663-78. PubMed ID: 12801588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
    Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
    Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
    Wtorek K; Janecka A
    Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.
    Jong L; Zaveri N; Toll L
    Bioorg Med Chem Lett; 2004 Jan; 14(1):181-5. PubMed ID: 14684324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
    Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2008 Mar; 16(5):2635-44. PubMed ID: 18068993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.